Epidemiology, pathophysiology, diagnosis of COPD and the implementation of GOLD guidelines – a short review

Article Sidebar

Cover page - Volume 2 Issue 3 Medical Science ISSN 2321-5291
Full text PDF
Published: Sep 30, 2014
DOI: https://doi.org/10.29387/ms.2014.2.3.135-140
Keywords:
COPD GOLD human chronic disease

Main Article Content

Girish Dandagi
Belgaum Institute of Medical sciences, Belgaum, Karnataka, India

Abstract

Chronic obstructive pulmonary disease (COPD) is a disorder characterized by reduced maximum expiratory flow and slow forced emptying of the lungs; features which do not change markedly over several months. Chronic bronchitis and emphysema are the two forms, but it is observed that most of the sufferers have a combination of both conditions. In the year 2007 guidelines from the Global Initiative for COPD was addressed and the management was clarified in detail. It provides evidence-based recommendations for COPD sufferers and doctors. Cessation of smoking, controlling the environmental indoor and outdoor pollutants is the main factors to be taken into consideration. GOLD was introduced with an aim of increase consciousness about COPD and to help millions of sufferers from premature death.

Article Details

How to Cite
Dandagi, G. (2014). Epidemiology, pathophysiology, diagnosis of COPD and the implementation of GOLD guidelines – a short review. Medical Science, 2(3), 135-140. https://doi.org/10.29387/ms.2014.2.3.135-140
Issue
Vol. 2 No. 3: Open Access
Section
Review Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 

 
 
Author Biography

Girish Dandagi, Belgaum Institute of Medical sciences, Belgaum, Karnataka, India

MD, Associate Professor, Department of TB and Chest diseases

References

Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398–1420.

COPD. Medline plus. Accessed on 17-09-2014 from URL:http://www.nlm.nih.gov/medlineplus/copd.html

McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, Wright AC, Gefter WB. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011 Oct 27;365(17):1567-75.

Yoshida T1, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev. 2007;87(3):1047-82.

Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med. 2000 Mar;21(1):67-86, viii.

Antó JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 2001;17(5):982-94.

MacNee W. Pathology, pathogenesis, and pathophysiology. BMJ. May 20, 2006; 332(7551): 1202–1204.

Higgins MW, Thom T. Incidence, prevalence and mortality: intra- and intercountry differences In: Hensley MJ, Saunders NA, editors. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease New York, Mercel Dekker Inc., 1989; pp. 23–42.

Sobradillo V, Miravitlles M, Jimenez CA, et al. Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation. Arch Bronconeumol 1999;35:159–166.

Lange P, Groth S, Nyboe J, et al. Chronic obstructive lung disease in Copenhagen: cross-sectional epidemiological aspects. J Inter Med 1989;226:25–32.

Bakke PS, Baste V, Hanoa R, et al. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991;46:863–870.

Regional COPD Working Group. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology. 2003;8(2):192-8.

Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709–721.

Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV,Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG.Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366:1875–1881.

Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis.Eur Respir J 2006;28:523–532.

Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, Takahashi K, Nishimura K, Ishioka S, Aizawa H, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 2004;9:458–465.

Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007. 15;176(6):532-55.

Klaus F. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine. 2007; 176: 533-555.

Global Initiative for Chronic Obstructive Lung Disease. GOLD guidelines. Accessed on 17-09-2014 from URL:http://www.goldcopd.org/uploads/users/files/GOLDReport07_0108.pdf

Pauwells RA, Buist S, Calverley PMA, Jenkins CR, Hurd SS and the GOLD Scientific Committee (NHLBI-WHO workshop summary). Global strategy for the diagnosis, management, and prevention of chronic obstructive disease. Am J Respir Crit Care Med 2001; 163: 1256–1276.

Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: 1072–1079.

Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 2006;173:1316–1325.